Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZYUS Life SciencesTSXV:ZYUS 16 9-Day RSI is 45.99 as of Aug. 03, 2026. GuruFocus rates TSXV:ZYUS with a GF Score™ of 16/100. The stock has 7 warning signs investors should review. Among 1,047 Drug Manufacturers companies, ZYUS Life Sciences ranks better than 99.62% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
ZYUS Life Sciences (TSXV:ZYUS) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
ZYUS Life Sciences 9-Day RSI Related Terms
TSXV:ZYUS vs RMTI, BTAI, MRMD: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's 9-Day RSI falls into.
ZYUS Life Sciences (TSXV:ZYUS) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYUS Life Sciences (TSXV:ZYUS) has a 9-Day RSI of 45.99 as of Aug. 03, 2026. According to the industry distribution chart, ZYUS Life Sciences ranks #4 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is ZYUS Life Sciences' 9-Day RSI too high?
ZYUS Life Sciences' current 9-Day RSI is 45.99. The Drug Manufacturers industry median 9-Day RSI is 47.24. ZYUS Life Sciences' value of 45.99 is 2.6% below this industry median. Based on the distribution chart, ZYUS Life Sciences ranks #4 out of 1047 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ZYUS Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' 9-Day RSI compare to RMTI and BTAI?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #4 out of 1047 companies for 9-Day RSI. This places ZYUS Life Sciences in the top 0% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 47.24. ZYUS Life Sciences' value of 45.99 is 2.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 47.24, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ZYUS Life Sciences's current 9-Day RSI of 45.99 is 2.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 47.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZYUS Life Sciences's current 9-Day RSI is 45.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
ZYUS Life Sciences (TSXV:ZYUS) has a current 9-Day RSI of 45.99. The current 9-Day RSI is 45.99 and 2.6% below the Drug Manufacturers industry median of 47.24. ZYUS Life Sciences' overall GF Score™ is 16/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For ZYUS Life Sciences (TSXV:ZYUS), the current 9-Day RSI is 45.99 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
16GF Score
Get the complete analysis for TSXV:ZYUS
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:ZYUS has been successfully added to your 
